Moxquin 400 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Moxifloxacin hydrochloride tablet |
| Company | Incepta pharmaceuticals ltd |
Indications
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Community acquired pneumonia
- Uncomplicated skin and skin structure infections
- Complicated skin and skin structure infections
- Complicated intra-abdominal infections
- Pelvic inflammatory disease
Pharmacology
Broad spectrum, fluoroquinolone class of antibacterial drug with activity against gram-positive, gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. Inhibits topoisomerase II (DNA gyrase) and topoisomerase IV.
Dosage & Administration
- Acute bacterial sinusitis: 400 mg once daily for 7-10 days
- Acute bacterial exacerbation of chronic bronchitis: 400 mg once daily for 5-10 days
- Community-acquired pneumonia: 400 mg once daily for 7-14 days
- Uncomplicated skin and skin structure infections: 400 mg once daily for 7 days
- Complicated skin and skin structure infections: 400 mg once daily for 7-21 days
- Complicated intra-abdominal infections: 400 mg once daily for 5-14 days
- Pelvic inflammatory disease: 400 mg once daily for 14 days
Interaction
Absorption is decreased when administered with antacids, sucralfate, multivitamins, and multivalent cations. May enhance the risk of convulsions with NSAIDs and bleeding with warfarin.
Contraindications
Patients with a history of hypersensitivity to Moxifloxacin or other quinolones
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Pregnancy & Lactation
US FDA pregnancy category C. Not recommended during pregnancy & lactation.
Precautions & Warnings
May cause an increased risk of tendinitis and tendon rupture. Should be discontinued if pain or inflammation in a tendon occurs. Should not be used in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA or Class III antiarrhythmic agents
Use in Special Populations
- Renal or hepatic impaired patients: No dose adjustment necessary
- Pediatric patients: Safety and effectiveness not established for pediatric patients and adolescents below 18 years of age
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep in a dry place, away from light and heat. Keep out of the reach of children.